---
title: "Novo Nordisk AS reported third-quarter sales of DKK 74.98 billion, estimated at DKK 76.68 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264358095.md"
description: "Novo Nordisk's third-quarter sales reached DKK 74.98 billion, estimated at DKK 76.68 billion. Risk warning and disclaimer: The market has risks, and investment should be cautious. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk"
datetime: "2025-11-05T06:35:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264358095.md)
  - [en](https://longbridge.com/en/news/264358095.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264358095.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264358095.md) | [繁體中文](https://longbridge.com/zh-HK/news/264358095.md)


# Novo Nordisk AS reported third-quarter sales of DKK 74.98 billion, estimated at DKK 76.68 billion

Novo Nordisk's third-quarter sales amounted to DKK 74.98 billion, estimated at DKK 76.68 billion.

Risk Warning and Disclaimer

The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk

### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [BREAKINGVIEWS-Novo Nordisk is Denmark’s big little problem: podcast](https://longbridge.com/en/news/280570178.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/en/news/281206892.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md)
- [Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program](https://longbridge.com/en/news/280885256.md)
- [Novo Nordisk A/S Approves Final Dividend for 2025, Payable in March 2026](https://longbridge.com/en/news/280694679.md)